SEC Form 4 · accession 0001012975-15-000437
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Nelsen
Director
Period of report
May 29, 2015
Accepted (ET)
Jun 2, 2015 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | May 29, 2015 | J | 300,000 | $0.00 | D | 2,402,516 | I | By ARCH Venture Fund VII, L.P. |
| Common Stock | May 29, 2015 | J | 1,733 | $0.00 | A | 8,422 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Distribution of Common Stock held by a limited partnership to its partners for no consideration.
- F2These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.
- F3Change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person.